325 related articles for article (PubMed ID: 12401330)
1. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions.
Hall FS; Li XF; Sora I; Xu F; Caron M; Lesch KP; Murphy DL; Uhl GR
Neuroscience; 2002; 115(1):153-61. PubMed ID: 12401330
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying the rewarding effects of cocaine.
Hall FS; Sora I; Drgonova J; Li XF; Goeb M; Uhl GR
Ann N Y Acad Sci; 2004 Oct; 1025():47-56. PubMed ID: 15542699
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.
Sora I; Hall FS; Andrews AM; Itokawa M; Li XF; Wei HB; Wichems C; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5300-5. PubMed ID: 11320258
[TBL] [Abstract][Full Text] [Related]
4. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.
Morón JA; Brockington A; Wise RA; Rocha BA; Hope BT
J Neurosci; 2002 Jan; 22(2):389-95. PubMed ID: 11784783
[TBL] [Abstract][Full Text] [Related]
5. Cocaine, reward, movement and monoamine transporters.
Uhl GR; Hall FS; Sora I
Mol Psychiatry; 2002; 7(1):21-6. PubMed ID: 11803442
[TBL] [Abstract][Full Text] [Related]
6. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice.
Sora I; Wichems C; Takahashi N; Li XF; Zeng Z; Revay R; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7699-704. PubMed ID: 9636213
[TBL] [Abstract][Full Text] [Related]
7. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects.
Belej T; Manji D; Sioutis S; Barros HM; Nobrega JN
Brain Res; 1996 Oct; 736(1-2):287-96. PubMed ID: 8930335
[TBL] [Abstract][Full Text] [Related]
8. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens.
Mateo Y; Budygin EA; John CE; Banks ML; Jones SR
J Neurosci Methods; 2004 Dec; 140(1-2):183-7. PubMed ID: 15589348
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
[TBL] [Abstract][Full Text] [Related]
10. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux.
Wall SC; Gu H; Rudnick G
Mol Pharmacol; 1995 Mar; 47(3):544-50. PubMed ID: 7700252
[TBL] [Abstract][Full Text] [Related]
11. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
Budygin EA; John CE; Mateo Y; Jones SR
J Neurosci; 2002 May; 22(10):RC222. PubMed ID: 12006604
[TBL] [Abstract][Full Text] [Related]
12. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity.
Miller GM; Yatin SM; De La Garza R; Goulet M; Madras BK
Brain Res Mol Brain Res; 2001 Feb; 87(1):124-43. PubMed ID: 11223167
[TBL] [Abstract][Full Text] [Related]
13. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships at monoamine transporters and muscarinic receptors for N-substituted-3alpha-(3'-chloro-, 4'-chloro-, and 4',4''-dichloro-substituted-diphenyl)methoxytropanes.
Newman AH; Robarge MJ; Howard IM; Wittkopp SL; George C; Kopajtic T; Izenwasser S; Katz JL
J Med Chem; 2001 Feb; 44(4):633-40. PubMed ID: 11170654
[TBL] [Abstract][Full Text] [Related]
15. 2'-Substitution of cocaine selectively enhances dopamine and norepinephrine transporter binding.
Seale TW; Avor K; Singh S; Hall N; Chan HM; Basmadjian GP
Neuroreport; 1997 Nov; 8(16):3571-5. PubMed ID: 9427328
[TBL] [Abstract][Full Text] [Related]
16. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
17. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function.
Mateo Y; Budygin EA; John CE; Jones SR
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):372-7. PubMed ID: 14691264
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics.
Sato T; Kitayama S; Mitsuhata C; Ikeda T; Morita K; Dohi T
Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):214-20. PubMed ID: 10685879
[TBL] [Abstract][Full Text] [Related]
19. Reduced MPTP toxicity in noradrenaline transporter knockout mice.
Rommelfanger KS; Weinshenker D; Miller GW
J Neurochem; 2004 Dec; 91(5):1116-24. PubMed ID: 15569255
[TBL] [Abstract][Full Text] [Related]
20. Cocaine self-administration in rats differentially alters mRNA levels of the monoamine transporters and striatal neuropeptides.
Arroyo M; Baker WA; Everitt BJ
Brain Res Mol Brain Res; 2000 Nov; 83(1-2):107-20. PubMed ID: 11072100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
